These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 10665477

  • 1. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.
    End DW.
    Invest New Drugs; 1999; 17(3):241-58. PubMed ID: 10665477
    [Abstract] [Full Text] [Related]

  • 2. Agents targeting ras signaling pathway.
    Dancey JE.
    Curr Pharm Des; 2002; 8(25):2259-67. PubMed ID: 12369854
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a Ras-independent mechanism of action.
    Karlson J, Borg-Karlson AK, Unelius R, Shoshan MC, Wilking N, Ringborg U, Linder S.
    Anticancer Drugs; 1996 Jun; 7(4):422-9. PubMed ID: 8826611
    [Abstract] [Full Text] [Related]

  • 4. Inhibitors of the ras oncogene as therapeutic targets.
    Ghobrial IM, Adjei AA.
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
    [Abstract] [Full Text] [Related]

  • 5. Ras family signaling: therapeutic targeting.
    Cox AD, Der CJ.
    Cancer Biol Ther; 2002 Oct; 1(6):599-606. PubMed ID: 12642680
    [Abstract] [Full Text] [Related]

  • 6. Kampanols: novel Ras farnesyl-protein transferase inhibitors from Stachybotrys kampalensis.
    Singh SB, Zink DL, Williams M, Polishook JD, Sanchez M, Silverman KC, Lingham RB.
    Bioorg Med Chem Lett; 1998 Aug 18; 8(16):2071-6. PubMed ID: 9873488
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
    Chen X, Hasuma T, Yano Y, Yoshimata T, Morishima Y, Wang Y, Otani S.
    Anticancer Res; 1997 Aug 18; 17(4A):2555-64. PubMed ID: 9252680
    [Abstract] [Full Text] [Related]

  • 8. Farnesyl transferase inhibitors--a novel therapy for breast cancer.
    Johnston SR, Kelland LR.
    Endocr Relat Cancer; 2001 Sep 18; 8(3):227-35. PubMed ID: 11566614
    [Abstract] [Full Text] [Related]

  • 9. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK, Windle JJ, Von Hoff DD.
    J Clin Oncol; 1999 Nov 18; 17(11):3631-52. PubMed ID: 10550163
    [Abstract] [Full Text] [Related]

  • 10. Re: Blocking oncogenic Ras signaling for cancer therapy.
    Canevari S, Biocca S, Figini M.
    J Natl Cancer Inst; 2002 Jul 03; 94(13):1031-2; author reply 1032. PubMed ID: 12096090
    [No Abstract] [Full Text] [Related]

  • 11. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
    Crul M, de Klerk GJ, Beijnen JH, Schellens JH.
    Anticancer Drugs; 2001 Mar 03; 12(3):163-84. PubMed ID: 11290863
    [Abstract] [Full Text] [Related]

  • 12. [How the therapy of cancer is changing].
    Lopez M.
    Clin Ter; 1999 Mar 03; 150(6):397-400. PubMed ID: 10756657
    [No Abstract] [Full Text] [Related]

  • 13. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F.
    Anticancer Drugs; 2002 Sep 03; 13(8):891-7. PubMed ID: 12394276
    [Abstract] [Full Text] [Related]

  • 14. Ras as a target in cancer therapy.
    Midgley RS, Kerr DJ.
    Crit Rev Oncol Hematol; 2002 Nov 03; 44(2):109-20. PubMed ID: 12413630
    [Abstract] [Full Text] [Related]

  • 15. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of farnesyl protein transferase and P21ras memebrane association by d-limonene in human pancreas tumor cells in vitro.
    Chen X, Yano Y, Hasuma T, Yoshimata T, Yinna W, Otani S.
    Chin Med Sci J; 1999 Sep 27; 14(3):138-44. PubMed ID: 12903812
    [Abstract] [Full Text] [Related]

  • 17. Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation.
    Bishop WR, Kirschmeier P, Baum C.
    Cancer Biol Ther; 2003 Sep 27; 2(4 Suppl 1):S96-104. PubMed ID: 14508086
    [No Abstract] [Full Text] [Related]

  • 18. XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase.
    Donaldson MJ, Skoumas V, Watson M, Ashworth PA, Ryder H, Moore M, Coombes RC.
    Eur J Cancer; 1999 Jun 27; 35(6):1014-9. PubMed ID: 10533487
    [Abstract] [Full Text] [Related]

  • 19. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E, Kantarjian H, Cortes J.
    Leuk Lymphoma; 2004 Nov 27; 45(11):2187-95. PubMed ID: 15512806
    [Abstract] [Full Text] [Related]

  • 20. [Signal transduction inhibitor].
    Ueda Y, Saijo N.
    Gan To Kagaku Ryoho; 2001 May 27; 28(5):591-600. PubMed ID: 11383206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.